Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Scientists from the US and Brazil have been exploring new treatment options for lung conditions using advanced technologies.
The research, published in the journal, Proceedings of the National Academy of Sciences, focused on how the emerging field of nanotechnology – using and controlling materials at a very minute level – could be used in the treatment of a range of lung conditions. These include cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma, among others.
The lungs contain a protective mucus barrier, designed to stop germs and other particles from entering the lungs. The barrier can cause problems for people with lung conditions who take inhaled medicines, in that it can prevent the medicines from getting to the right place.
Scientists used tiny nanoparticles to develop an inhalable ‘wrapper’ to contain therapeutic genes. They found that this system was effective in getting the genes through the barrier.
However, it is worth noting that this research is still at a very early stage, and more studies are needed to test and refine the method. The scientists behind it say that it could be many years before this type of technology could be used to help treat people with lung conditions.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.